- ►annals.org [PDF] CW Francis, BL Davidson, SD Berkowitz, PA … - Annals of internal medicine, 2002 - Am Coll Physicians Background: Warfarin is used for prophylaxis of venous throm- boembolism in
patients undergoing total knee arthroplasty. How- ever, it is associated with
rates of deep venous thrombosis (DVT) of approximately 38% to 55% and ... Cited by 212 - Related articles - All 6 versions
BI Eriksson, P Kälebo, D Bergqvisty, OE Dahl, … - The Lancet, 2002 - Elsevier Of 1900 patients, 1495 were assigned to four dose categories of subcutaneous
melagatran from just before surgery (1·00 mg, 1·50 mg, 2·25 mg, or 3·00 mg
twice daily) followed from the day after surgery by oral ximelagatran (8 ... Cited by 251 - Related articles - All 10 versions
JA Heit, CW Colwell, CW Francis, JS Ginsberg … - Archives of Internal Medicine, 2001 - Am Med Assoc Methods We performed a randomized, parallel, dose-finding study of 600 adults
undergoing elective total knee replacement at 68 North American hospitals to
determine the optimum dose of ximelagatran to use as prophylaxis against ... Cited by 143 - Related articles - All 4 versions
BI Eriksson, G Agnelli, AT Cohen, OE Dahl, … - Journal of Thrombosis and Haemostasis, 2003 - ingentaconnect.com Background: Ximelagatran and its subcutaneous (sc) form melagatran are novel
direct thrombin inhibitors for the prevention and treatment of thromboembolic
disease. Methods: In a double-blind study, 2835 consecutive patients ... Cited by 260 - Related articles - BL Direct - All 6 versions
CW Francis, SD Berkowitz, PC Comp, JR … - The New England journal of medicine, 2003 - nejm.highwire.org From the Department of Medicine, Univer- sity of Rochester, Rochester, NY (CWF);
the Department of Clinical Development, AstraZeneca, Wilmington, Del. (SDB, GRP,
AWR, JM); the Department of Medicine, University of Oklahoma, Okla- homa ... Cited by 283 - Related articles - BL Direct - All 13 versions
CW Colwell, SD Berkowitz, BL Davidson, PA … - Journal of Thrombosis and Haemostasis, 2003 - ingentaconnect.com Background: Prophylaxis is recommended following total joint replacement because
of the high risk of venous thromboembolism (VTE). Postoperative
low-molecular-weight heparin (LMWH) reduces the incidence of ... Cited by 120 - Related articles - BL Direct - All 2 versions
BI Eriksson, AC Arfwidsson, L Frison, UG … - Thrombosis and haemostasis, 2002 - ncbi.nlm.nih.gov The novel, oral direct thrombin inhibitor, ximelagatran (formerly H 376/95),
represents an advance in antithrombotic therapy through its oral availability.
After oral administration, ximelagatran is converted to its active form, ... Cited by 136 - Related articles - BL Direct - All 3 versions
UG Eriksson, U Bredberg, K Gislén, LC … - European journal of clinical pharmacology, 2003 - Springer Abstract Objectives: Ximelagatran is a novel, oral direct thrombin inhibitor
designed to overcome the low and variable oral absorption of melagatran, its
active form. The pharmacokinetics and pharmacodynamics of ximelagatran ... Cited by 168 - Related articles - BL Direct - All 7 versions
- ►adisonline.com [PDF] LC Johansson, L Frison, U Logren, G Fager, … - Clinical pharmacokinetics, 2003 - ingentaconnect.com Arterial and venous thromboembolism are the largest single causes of disease and
death in the western world. They cause, or contribute to, unsta- ble angina,
acute myocardial infarction, [1] embolic and thrombotic stroke, [2,3] ... Cited by 130 - Related articles - BL Direct - All 7 versions
H Eriksson, K Wahlander, D Gustafsson, L … - Journal of Thrombosis and Haemostasis, 2003 - interscience.wiley.com Summary. This randomized, controlled, multicentre study evaluated the efficacy
and tolerability of the oral direct thrombin inhibitor ximelagatran, compared
with a low-molecular-weight heparin (dalteparin) followed by warfarin, in ... Cited by 122 - Related articles - All 3 versions
